#APVO

Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality Aptevo Therapeutics (NASDAQ: APVO) entered a $60 million equity line of credit with Yorkville Advisors to provide incremental, market-based capital access. Combined with cash on hand, the fully leveraged facility is stated to extend Aptevo's funding runway into 2029 to support clinical and preclinical multispecific oncology programs. Proceeds will fund ongoing clinical development, advance preclinical programs, and general corporate purposes. The company retains discretion to draw on the facility; terms note minimal fees and no warrants. Aptevo's pipeline includes five CD3-engaging assets led by mipletamig (CD123×CD3), evaluated in >100 patients with reported high remission rates and no observed cytokine release syndrome in frontline patients to date.

2 months ago

#APVO Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality

www.stocktitan.net/news/APVO/aptevo-therape...

0 0 0 0

PRISM MarketView

@prismmarketview.bsky.social

2 months ago

PRISM Morning Movers
Premarket Gainers:
Davis Commodities Limited. ( #DTCK) up 97%
Can-Fite BioPharma Ltd. ( #CANF) up 48%
A Space III Acquisition Corp. ( #ASPC) up 43%
Sidus Space, Inc. ( #SIDU) up 33%
Premarket Decliners:
Aptevo Therapeutics Inc. ( #APVO) dawn -21%
Pearson plc ( #PSO) down -13%

0 0 0 0

Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split SEATTLE, WA / ACCESS Newswire / December 26, 2025 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced that it will conduct

2 months ago

#APVO Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split

www.stocktitan.net/news/APVO/aptevo-therape...

0 0 0 0

Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025 100% of patients in Cohorts 1-3 remain free of cytokine release syndromeCRIS-7-derived CD3 design underpins a controlled T-cell response, supporting the differentiated safety profile, combinability with standard of careSEATTLE, WA / ACCESS Newswire / December 9, 2025 / Aptevo Therapeutics Inc.

3 months ago

#APVO Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025

www.stocktitan.net/news/APVO/aptevo-therape...

0 0 0 0

Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors First data on Aptevo's new molecule presented at the Society for Immunotherapy of Cancer (SITC) Annual MeetingSEATTLE, WASHINGTON / ACCESS Newswire / November 10, 2025 / Aptevo Therapeutics ("Aptevo" or the "Company") (Nasdaq:APVO), a clinical-stage biotechnology company advancing differentiated

4 months ago

#APVO Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors

www.stocktitan.net/news/APVO/aptevo-debuts-...

0 0 0 0

Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update 89% of evaluable mipletamig patients achieve remission in combination therapy for frontline AML across two trialsIntroduces first trispecific molecules, APVO451 and APVO452, advancing therapies designed to overcome immune suppression in certain solid tumorsBoth molecules leverage Aptevo's unique

4 months ago

#APVO Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update

www.stocktitan.net/news/APVO/aptevo-therape...

0 0 0 0

Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter Aptevo (Nasdaq:APVO) announced participation in multiple financial, industry and scientific conferences in Q4 2025 to highlight clinical and R&D progress.Key events: ROTH Healthcare Opportunities – Oct 9, 2025 (NYC): panel on novel AML therapies and mipletamig trial outcomes.BIO-Europe – Nov 3-5, 2025 (Vienna) with digital partnering Nov 11-12.SITC 2025 – Nov 5-9: R&D poster on a trispecific targeting Nectin-4, CD3 and CD40.ASH 2025 – Dec 6-9: interim Phase 1b/2 RAINIER results for mipletamig in frontline AML.Investor meetings available by contacting investor relations.

5 months ago

#APVO Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter

www.stocktitan.net/news/APVO/aptevo-present...

0 0 0 0

@wallstreetpulse.bsky.social

5 months ago

🚀 Exciting times for #APVO! Trading at $1.88 with bullish momentum and a 6-day RSI of 76.29, this stock is catching eyes with volume spikes and positive sentiment around its leukemia drug. Consider a long position targeting $2.00-$2.20, but stay cautious of overbought signals! 📈 #Stocks #Biotech

1 0 0 0

5 months ago

$APVO Stock Analysis, Aptevo Therapeutics Inc YouTube video by Hisseseven

$APVO Stock Analysis, Aptevo Therapeutics Inc youtu.be/tFGHeBK6wro?... @YouTube aracılığıyla #APVO #AptevoTherapeutics #APVOStock #StockAnalysis #TechnicalAnalysis #ShortSqueeze #VolatileStocks #VolumeSpike #SupportResistance #VWAP #ATR #BreakoutSetup

0 0 0 0

5 months ago

🚀 Big moves for #APVO! With a price at $1.52 and volume soaring past 4M, this stock is buzzing! 📈 RSI hints oversold, but MACD teases a bullish reversal. Consider a short-term play: enter at $1.50, target $1.70-$2.00, stop loss at $1.40. Stay sharp on news! #Stocks #Trading

0 0 0 0

5 months ago

🚀 Exciting times for #APVO! With a volume surge and bullish momentum, it's trading at $2.89, smashing past its 10, 20, and 30-day SMAs. RSI suggests room to grow, and a positive MACD adds fuel. Consider going long with targets at $3.20 & $3.50. Stop loss: $2.60. 📈 #FeetrAI

1 0 0 0

100% Remission Rate: Aptevo's Novel AML Drug Shows Perfect Response in Latest Trial Cohort, Zero Toxicity Mipletamig achieves 100% remission in Cohort 3 of RAINIER trial for frontline AML, with 40% MRD-negative status. No dose-limiting toxicities observed. Cohort 4 now enrolling.

5 months ago

#APVO Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML

www.stocktitan.net/news/APVO/mipletamig-del...

1 0 0 0

Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules Aptevo Therapeutics (NASDAQ:APVO) has expanded its oncology pipeline with two new trispecific candidates, APVO452 and APVO451, targeting prostate cancer and multiple solid tumors. These therapeutics leverage the company's proprietary ADAPTIR-FLEX platform and build upon clinical validation from mipletamig, their lead CD3-directed candidate.APVO452 targets PSMA, CD3, and CD40 for prostate cancers, while APVO451 targets Nectin-4, CD3, and CD40 for various solid tumors. Both therapeutics are designed to simultaneously engage tumor antigens, activate T cells, and modulate immunosuppressive cells in the tumor microenvironment.This expansion brings Aptevo's pipeline to eight bispecific and trispecific candidates, including five molecules utilizing their CRIS-7-derived CD3 pathway, positioning them as a leader in next-generation T cell engagers for both hematologic and solid tumor cancers.

6 months ago

#APVO Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules

www.stocktitan.net/news/APVO/aptevo-unveils...

0 0 0 0

Aptevo's New Prostate Cancer Drug Shows Promise with Targeted Immune Response Technology Novel bispecific antibody APVO442 targets $24B prostate cancer market with precision T-cell activation technology. Built on validated platform showing reduced toxicity. See details.

7 months ago

#APVO Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer

www.stocktitan.net/news/APVO/aptevo-highlig...

0 0 0 0

Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update Aptevo Therapeutics (Nasdaq:APVO) reported Q2 2025 financial results and significant clinical progress. The company's lead candidate mipletamig achieved an 85% remission rate in frontline AML patients across two trials. Aptevo expanded its CD3 bispecific portfolio by introducing APVO455, a Nectin-4 x CD3 bispecific targeting multiple solid tumors.The company raised $15.9 million in Q2 2025, extending its cash runway into late Q4 2025, with an additional $25 million equity line of credit secured. Q2 financial results showed cash position of $9.4 million and a net loss of $6.2 million ($8.40 per share), compared to a $5.9 million loss in Q2 2024.

7 months ago

#APVO Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update

www.stocktitan.net/news/APVO/aptevo-therape...

0 0 0 0

8 months ago

🚨 FeetrAI Alert: #APVO is in the spotlight! Trading at $3.77, it's showing bearish momentum with a 10-day SMA of $4.13 and RSI below 50. Consider a SHORT at $3.80, targeting $3.50 & $3.30. Stop loss at $4.00. Watch for volume spikes or news! 📉 #StockMarket #TradingTips

0 0 0 0

8 months ago

🚨 FeetrAI Alert: #APVO is in the spotlight! Trading at $4.08, it's below key moving averages with weak momentum. High volatility follows an 85% leukemia remission rate news, but watch out for dilution concerns. Short at $4.10? Targets: $3.80 & $3.50. Stop loss: $4.30. 📉 #BiotechBuzz

0 0 0 0

8 months ago

🚨 FeetrAI Alert: #APVO is in the spotlight! Trading at $4.08, it's below key SMAs, hinting bearish vibes. RSI suggests a bounce, but MACD shows potential reversal. Short at $4.10? Target $3.80/$3.50, stop loss $4.30. Caution: volatility & biotech risks ahead! 📉💡 #Stocks #Biotech

0 0 0 0

8 months ago

🚨 Hot take on #APVO! Trading at $4.51 with a tiny market cap of $2.96M, this low-float stock is buzzing with volatility! 📈 Mixed signals: Bullish MACD but neutral RSI. Short play? Enter at $4.60, target $4.30/$4.00, stop loss $4.80. FeetrAI's got the insights! 🔍📊 #Stocks #TradingTips

0 0 0 0